Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03706053 · ClinicalTrials.gov registry record · Phase 3
Midodrine Use in Septic Shock
A Phase 3 study, sponsored by University of Virginia.
- Terminated
- Registry status
- Phase 3
- Development phase
- 10
- Enrollment target
NCT03706053: Clinical Trial Phase 3 study, sponsored by University of Virginia.
NCT03706053 is a Phase 3 study that was terminated before completion, run by University of Virginia. The registered enrollment target is 10 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03706053, a Phase 3 study, was terminated before completion, sponsored by University of Virginia.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 10 participants
- Enrollment target
Study Summary
The investigators aim to perform a randomized, double-blind, placebo-controlled trial to investigate the efficacy of midodrine in decreasing time to IV vasopressor liberation in patients with septic shock.
Primary Outcome
days without vasopressor adjusted with mortality
Interventions
- OTHER placebo
- DRUG Midodrine Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-11-05 |
| Est. Completion | 2022-02-11 |
| Phase | Phase 3 |
Why NCT03706053 stopped before completion
NCT03706053 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT03706053 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03706053 about?
NCT03706053 is a clinical study titled "Midodrine Use in Septic Shock". The investigators aim to perform a randomized, double-blind, placebo-controlled trial to investigate the efficacy of midodrine in decreasing time to IV vasopressor liberation in patients with septic shock.
What is the current status of trial NCT03706053?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 10 participants. The study started on 2018-11-05. Estimated completion is 2022-02-11.
What interventions are being tested in trial NCT03706053?
The interventions under investigation include: placebo (OTHER), Midodrine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT03706053?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03706053's enrollment target sits among peer trials
10 1989th of 2000 higher than 9 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI